WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012112626) COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/112626    International Application No.:    PCT/US2012/025140
Publication Date: 23.08.2012 International Filing Date: 14.02.2012
IPC:
A61K 38/05 (2006.01)
Applicants: INTARCIA THERAPEUTICS, INC. [US/US]; 24650 Industrial Blvd Hayward, CA 94545 (US) (For All Designated States Except US).
LEUNG, Karling, Alice [US/US]; (US) (For US Only)
Inventors: LEUNG, Karling, Alice; (US)
Agent: ELRIFI, Ivor, R.; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO, P.C. One Financial Center Boston, MA 02111 (US)
Priority Data:
61/443,628 16.02.2011 US
Title (EN) COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCERS
(FR) COMPOSITIONS, DISPOSITIFS ET PROCÉDÉS D'UTILISATION DE CELLES-CI DANS LE TRAITEMENT DES CANCERS
Abstract: front page image
(EN)The use of GLP-1 receptor agonists, such as glucagon-like peptide- 1 (GLP-1) or exenatide, for the treatment of cancer is described. The GLP-1 receptor agonists are typically delivered using an implanted osmotic delivery device that provides for continuous delivery of the GLP-1 receptor agonist for at least one month. Additional beneficial agents, such as anticancer agents, can also be administered.
(FR)La présente invention concerne l'utilisation d'agonistes des récepteurs GLP-1, tels que le peptide-1 de type glucagon (GLP-1) ou l'exenatide, dans le traitement du cancer. Les agonistes des récepteurs GLP-1 sont typiquement administrés en utilisant un dispositif implanté d'administration osmotique permettant d'avoir une administration continue d'agonistes des récepteurs GLP-1 pendant au moins un mois. D'autres agents bénéfiques, tels que des agents anti-cancéreux, peuvent également être administrés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)